Zentiva Sold for 100 billion CZK

In the largest Czech acquisition in recent years, the American investment fund GTCR will acquire the Czech pharmaceutical manufacturer Zentiva from Advent International for 100 billion CZK. Advent had previously purchased the company in 2018 for 49 billion CZK. Zentiva focuses primarily on the development and production of generic drugs, i.e., medications that can be substituted for the original drug after its patent expires. In 2024, Zentiva produced more than 588 million doses in its factories in Prague, Romania, and India, that reached around 100 million people. Its revenues reached 42 billion CZK, with an EBITDA of 10 billion CZK. The company operates in 30 countries and employs over 5,000 people.

Advent International is one of the world’s largest private equity firms. It manages 435 companies across 44 countries with a total value exceeding 100 billion USD. It focuses primarily on the financial services, healthcare, industrial, consumer, and technology sectors.

GTCR is an American private equity firm that focuses on identifying strong companies and turning them into market leaders. Globally, it holds stakes in over 290 companies and manages capital worth 50 billion USD.